A Message from Veracyte’s CEO About COVID-19     Learn More
A Message from Veracyte’s CEO About COVID-19     Learn More
Skip to content
PRESS RELEASES

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary Veracyte Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Aug. 7, 2020-- Veracyte, Inc. (Nasdaq: VCYT) announced today the closing of its public offering of 6,900,000 shares of common stock, including 900,000 shares sold upon full exercise of the underwriters’ option to purchase additional shares, at a price
View HTML
Toggle Summary Veracyte Announces New Real-World Data Reinforcing the Potential Clinical Value of Percepta and Envisia Classifiers to Improve Diagnosis of Serious Lung Diseases
ePosters presented during ATS 2020 Virtual conference SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Aug. 5, 2020-- Veracyte, Inc . (Nasdaq: VCYT) announced today that data presented at the American Thoracic Society 2020 Virtual conference reinforce the potential clinical value of the company’s
View HTML
Toggle Summary Veracyte Announces Positive Clinical Utility Data for Percepta Classifier Published in CHEST
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Aug. 5, 2020-- Veracyte, Inc . (Nasdaq: VCYT) today announced the publication of new data demonstrating that the Percepta ® classifier significantly reduces invasive procedures in lung cancer diagnosis by classifying nearly 40 percent of patients as
View HTML
Toggle Summary Veracyte Announces Pricing of Public Offering of 6,000,000 Shares of Common Stock
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Aug. 4, 2020-- Veracyte, Inc. (Nasdaq: VCYT) (the “Company”) today announced the pricing of an underwritten public offering of 6,000,000 shares of its common stock at a public offering price of $30.00 per share.
View HTML
Toggle Summary Veracyte Announces Proposed Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Aug. 3, 2020-- Veracyte, Inc. (Nasdaq: VCYT) (the “Company”) today announced that it has commenced an underwritten public offering of 6,000,000 shares of its common stock. All of the shares are being offered by Veracyte .
View HTML
Toggle Summary Veracyte Announces Second Quarter 2020 Financial Results
Revenue of $20.7 Million and Genomic Testing Volume of 5,379 Company Advances Pipeline and Global Expansion Strategy Conference Call and Webcast Today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jul. 30, 2020-- Veracyte, Inc . (Nasdaq: VCYT) today announced financial results for
View HTML
Toggle Summary Veracyte Announces Data Published in AJRCCM Showing That the Envisia Genomic Classifier Improves Physicians’ Ability to Diagnose IPF Without Surgery
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jul. 30, 2020-- Veracyte, Inc . (Nasdaq: VCYT) today announced new study results showing that use of the Envisia ® Genomic Classifier improves physicians’ ability to diagnose idiopathic pulmonary fibrosis (IPF) and other interstitial lung diseases
View HTML
Toggle Summary Veracyte and MAVIDx Announce Agreement for MAVIDx to Develop Ultra-High Volume COVID-19 Testing on the nCounter System
Novel approach may enable processing of over 40,000 patient samples per day using molecular barcodes for viral RNA SOUTH SAN FRANCISCO, Calif. , and MIAMI --(BUSINESS WIRE)--Jul. 29, 2020-- Veracyte, Inc . (Nasdaq: VCYT) and MAVIDx today announced an agreement for MAVIDx to develop ultra-high
View HTML
Toggle Summary Veracyte Appoints Jens Holstein to Board of Directors and James (Jim) Erlinger as Executive Vice President, General Counsel and Secretary
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jul. 27, 2020-- Veracyte, Inc. (Nasdaq: VCYT), a global genomic diagnostics company, today announced the addition of Jens Holstein to the company’s board of directors and the appointment of Jim Erlinger as executive vice president, general counsel and
View HTML
Toggle Summary Veracyte to Release Second Quarter 2020 Financial Results on July 30, 2020
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jul. 16, 2020-- Veracyte, Inc . (Nasdaq: VCYT) announced today that it will release its financial results for the second quarter of 2020 after the close of market on Thursday, July 30, 2020 . Company management will host a conference call and webcast
View HTML